Carmen Allegra, M.D.

Carmen J Allegra, M.D. - Research & Publications

(352) 265-0725

Request an Appointment

Publications

Oxaliplatin as Adjuvant Therapy for Colon Cancer: Updated Results of Nsabp C-07 Trial, Including Survival and Subset Analyses
Journal of Clinical Oncology
2019

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
Journal of Clinical Oncology
2019

Defective Mismatch Repair and Benefit From Bevacizumab for Colon Cancer: Findings From Nsabp C-08
Journal of Clinical Oncology
2019

Alternative End Points To Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time To Failure of Strategy-An Aide Et Recherche En Cancerologie Digestive Group Study
Journal of Clinical Oncology
2019

Don Quixote and the Quest for Personalized Medicine
Journal of Clinical Oncology
2019

Association of Obesity With Dna Mismatch Repair Status and Clinical Outcome in Patients With Stage Ii Or Iii Colon Carcinoma Participating in Ncctg and Nsabp Adjuvant Chemotherapy Trials
Annals of Surgical Oncology
2019

Nsabp Fc-6: Phase II Study To Determine Surgical Conversion Rate in Patients (Pts) Receiving Neoadjuvant (Na) Mfolfox7 Plus Dose-Escalating Cetuximab (C) for Unresectable K-Ras Wild-Type (Wt) Colorectal Cancer With Metastases (Mcrc) Confined To the Liver
Journal of Clinical Oncology
2019

Extended Ras Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015
Plos One
2019

Continuous Publication of Jnci
Annals of Oncology
2019

Molecular Subtypes of Colorectal Cancer in Pre-Clinical Models Show Differential Response to Targeted Therapies: Treatment Implications Beyond Kras Mutations
Journal of Clinical Oncology
2019

Aflibercept Versus Placebo in Combination With Folfiri in Previously Treated Metastatic Colorectal Cancer: Mean Overall Survival for Subgroups From Velour
Annals of Oncology
2019

The Marriage of Growth Factor Inhibitors and Chemotherapy: Bliss Or Bust?
International Journal of Cancer
2019

National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009.
Journal of Clinical Oncology
2019

Multiagent Regimens for Metastatic Colorectal Cancer: If Some Is Good, More Must Be Better
Journal of Clinical Oncology
2019

Intravenous (Iv) Aflibercept Versus Placebo in Combination With Irinotecan/5-Fu (Folfiri) for Second-Line Treatment of Metastatic Colorectal Cancer (Mcrc): Results of a Multinational Phase III Trial (Efc10262-Velour).
Clinical pharmacology and therapeutics
2019

Analysis of 320 Gastroenteropancreatic Neuroendocrine Tumors Identifies Ts Expression as Independent Biomarker for Survival
Archives of Pathology & Laboratory Medicine
2019

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of Nsabp Protocol C-08
Cancer
2019

Addition of Aflibercept To Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With An Oxaliplatin-Based Regimen
Oncology
2019

Therapeutic Drug Monitoring in Oncology: IATDMCT Recommendations for 5-Fluorouracil Therapy.
British Journal of Cancer
2019

The Journal of the National Cancer Institute: the Next Generation
Journal of Clinical Oncology
2019

National Institutes of Health State-Of-The-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma in Situ September 22-24, 2009
Journal of Clinical Oncology
2019

Accent-Based Web Calculators To Predict Recurrence and Overall Survival in Stage III Colon Cancer
Clinical Advances in Hematology and Oncology
2019

Molecular Biomarkers for the Evaluation of Colorectal Cancer Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology
Annals of Oncology
2019

Rectal cancer patients younger than 50 years lack a survival benefit from NCCN guideline-directed treatment for stage II and III disease.
Jama Oncology
2019

Combination Therapy for Renal Cell Cancer: What Are Possible Options?
Annals of Oncology
2019

Mean Overall Survival Gain With Aflibercept Plus Folfiri Vs Placebo Plus Folfiri in Patients With Previously Treated Metastatic Colorectal Cancer
European Journal of Cancer
2019

Initial Safety Report of Nsabp C-08: a Randomized Phase III Study of Modified Folfox6 With Or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II Or III Colon Cancer
Journal of Clinical Oncology
2019

Neoadjuvant 5-Fu or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: a Phase III Randomized Clinical Trial

2019

Bevacizumab in Stage Ii-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial

2019

Effective salvage treatment of recurrent Ewing sarcoma utilizing chemotherapy and zoledronic acid.

2019

Aflibercept/Folfiri (Af) Vs Placebo/Folfiri (Pf) in Metastatic Colorectal Cancer (Mcrc): Post-Hoc Analysis of Survival Excluding Adjuvant (Adj)-Only Patients in the Velour Trial

2019

Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes Secondary Analysis of Nsabp C-O7/Nrg Oncology Randomized Clinical Trial

2019

Sensitivity Analyses of Progression-Free Survival (Pfs) of Aflibercept-Folfiri Versus Placebo-Folfiri in Metastatic Colorectal Cancer (Mcrc): Results From the Velour Study

2019

Aflibercept Versus Placebo in Combination With Fluorouracil, Leucovorin and Irinotecan in the Treatment of Previously Treated Metastatic Colorectal Cancer: Prespecified Subgroup Analyses From the Velour Trial

2019

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology

2019

Research Interests

His primary research effort is focused on developing new therapeutic strategies for patients with GI malignancies through the identification and translation of novel laboratory discoveries and therapeutic agents. This work is underpinned by new target discovery and identification of prognostic and predictive signatures required to personalize oncologic therapeutics.